Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker CRIS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed o… NCT03328078 · Relapsed Hematologic Malignancy, Refractory Hematologic Mal… Emavusertib, Ibrutinib | CRIS Curis, Inc. | Phase 1/2 | Recruiting | 152 | Jul 2027 | Registry ↗ |
| Jun 12, 2026 | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With C… NCT07271667 · Chronic Lymphocytic Leukemia, B-cell Malignancies Emavusertib, Zanubrutinib | CRIS Curis, Inc. | Phase 2 | Recruiting | 108 | Nov 2027 | Registry ↗ |
| Mar 19, 2026 | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leuke… NCT04278768 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome Emavusertib, Venetoclax | CRIS Curis, Inc. | Phase 1/2 | Suspended | 366 | Apr 1, 2026 | Registry ↗ |
| Oct 27, 2023 | Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies NCT04475523 · Solid Tumor CI-8993 | CRIS Curis, Inc. | Phase 1 | Completed | 26 | May 19, 2023 | Registry ↗ |
| Apr 27, 2022 | Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients… NCT02674750 · Relapsed and/or Refractory Diffuse Large B-cell Lymphoma In… CUDC-907 | CRIS Curis, Inc. | Phase 2 | Completed | 70 | May 28, 2019 | Registry ↗ |
| May 6, 2021 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patient… NCT01742988 · Lymphoma, Relapsed Lymphoma fimepinostat, Rituximab | CRIS Curis, Inc. | Phase 1 | Completed | 106 | Oct 9, 2020 | Registry ↗ |
| Jun 26, 2020 | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tum… NCT02812875 · Advanced Solid Tumors or Lymphomas CA-170 | CRIS Curis, Inc. | Phase 1 | Completed | 71 | May 7, 2020 | Registry ↗ |
| Sep 3, 2019 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907… NCT02307240 · Triple-Negative Breast Cancer, High-grade Serous Ovarian Ca… CUDC-907 | CRIS Curis, Inc. | Phase 1 | Completed | 43 | May 31, 2019 | Registry ↗ |
| Feb 22, 2018 | Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer NCT01384799 · Head and Neck Cancer CUDC-101, Cisplatin | CRIS Curis, Inc. | Phase 1 | Completed | 12 | Sep 2013 | Registry ↗ |
| Feb 22, 2018 | A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients Wi… NCT00728793 · Tumors CUDC-101 | CRIS Curis, Inc. | Phase 1 | Completed | 25 | Apr 2010 | Registry ↗ |
| Feb 12, 2018 | Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-… NCT01702285 · Cancer CUDC-101 | CRIS Curis, Inc. | Phase 1 | Terminated | 3 | Dec 2012 | Registry ↗ |
| Dec 1, 2016 | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Pat… NCT01908413 · Lymphoma CUDC-427 | CRIS Curis, Inc. | Phase 1 | Terminated | 23 | Mar 2015 | Registry ↗ |
| Mar 1, 2016 | A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous… NCT01171924 · Head and Neck Cancer, Liver Cancer CUDC-101, CUDC-101 | CRIS Curis, Inc. | Phase 1 | Completed | 47 | Oct 2011 | Registry ↗ |
13 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:14 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances